Pure Global
NCT03333954

Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration

Pixium Vision SA·ClinicalTrials.gov·device·Device trialActive, not recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Age-related Macular Degeneration
Drug/Device/Intervention
PRIMA
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Pixium Vision SA
Location
Paris, France
Timeline & enrollment
Phase
N/A
Start date
Nov 06, 2017
End date
Aug 27, 2024
Enrollment
5 participants
Primary outcome

Elicitation of perception,Elicitation of perception,Elicitation of perception,Elicitation of perception,Elicitation of perception,Elicitation of perception,Elicitation of perception

Summary

In this study, the principle functionality of the device will be tested in humans for the
 first time. The study will evaluate the extent to which patients with atrophic dry age
 related macular degeneration (AMD) have evoked light perception using the implant.

ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03333954
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT03333954 through Pure Global AI's free database. This phase not specified trial is sponsored by Pixium Vision SA and is currently Active, not recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 5 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.